Better Phase II Could Allow For More Single-Trial Approvals, Temple Says
Increased emphasis on Phase II trials could improve drug development and potentially allow more drug approvals based on a single Phase III clinical trial, Center for Drug Evaluation & Research Associate Director for Medical Policy Robert Temple, MD, suggested Jan. 15
You may also be interested in...
A single, well-controlled efficacy trial supported by confirmatory evidence may establish pharmacological causality better than traditional trial replication, Lewis Sheiner, MD, University of California-San Francisco, told a Drug Information Association meeting Jan. 22.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials